Press Releases

The following are official statements issued by UsAgainstAlzheimer’s in response to major national policy actions, industry events, breaking news, or organizational achievements. Please see the UsAgainstAlzheimer’s press kit page for additional information. For media requests, please contact Jon Summers at

  • September 28, 2022

    Lecanemab’s Positive Clinical Trial Results Give Alzheimer’s Patients Hope

    Alzheimer’s patients and their loved ones have new reason for hope following...

    Read more
  • September 27, 2022

    Months After Denying Medicare Coverage for Alzheimer’s Drugs, CMS Announces a Premium Cut

    The Centers for Medicare and Medicaid Services (CMS) has announced it plans...

    Read more
  • August 08, 2022

    FDA Deals Major Blow to Patients with Alzheimer’s-Related Psychosis

    Yesterday, Acadia Pharmaceuticals announced that it has been told by the FDA...

    Read more
  • July 18, 2022

    UsAgainstAlzheimer’s Urges CMS to Reconsider Rule Limiting Access to PET Scans

    Washington, D.C. (July 15, 2022) – UsAgainstAlzheimer’s chair and co-founder George Vradenburg ...

    Read more
  • June 30, 2022

    Major Win for Alzheimer’s Patients as U.S. House Committee Announces Significant Investments in Fighting Alzheimer’s

    Washington, D.C. – The fight to end Alzheimer’s got a major boost...

    Read more
  • June 28, 2022

    New Data Shows Hope for Reducing Agitation in Alzheimer’s Patients

    Washington, D.C. – Today, UsAgainstAlzheimer’s hailed the release of a new data...

    Read more
  • June 23, 2022

    UsAgainstAlzheimer’s Statement on Passage of the Advanced Research Projects Agency for Health (ARPA-H) Act (H.R. 5585)

    Washington, DC (June 22, 2022)— Today, UsAgainstAlzheimer’s issued the following statement...

    Read more
  • June 17, 2022

    UsAgainstAlzheimer’s Board Member Testifies on Alzheimer’s-Related Psychosis Before FDA Advisory Committee

    Washington, DC (June 17, 2022)— Today, UsAgainstAlzheimer’s Board Member Meryl Comer...

    Read more
  • June 17, 2022

    UsAgainstAlzheimer’s Statement on Crenezumab Trial Results

    Washington, DC (June 16, 2022) — Today, UsAgainstAlzheimer’s Chair and co-founder George...

    Read more

Place & Brain Health Equity: Understanding the County-Level Impacts of Alzheimer’s

The effects of where people live, and the social determinants of health are under-recognized and under-appreciated in our national response to effectively treat and prevent Alzheimer's. This report found that deep social inequities exist in countries highly impacted by Alzheimer's among Latinos and Blacks.